‘Personalised Medicine' in Oncology: Physicians' Perspectives on Contributions to and Challenges for Clinical Practice 1

So-called ‘personalised medicine’ as a genomic-based stratification of patient groups ³ has been part of many controversies in the public and scientific sphere (Cascorbi, 2010). Within medicine, the phrase stands as a symbol for new developments and hopes for future progress in prevention, diagnostics and therapy (Hempel, 2009; Hamburg and Collins, 2010; Siegmund-Schultze, 2011). However, there are also critical remarks such as reference to the current scarcity of solid evidence for targeted therapy and questions regarding the financing of effective measures for often small patient groups within a public health-care system (Browman et al., 2011; Ludwig, 2012; Vollmann, 2013).